Eli Lilly (LLY 1.16%) currently has several blockbuster drugs on the market -- but lookout investors, there are patent expirations aplenty for this pharma giant ahead. Much like Merck (MRK +1.51%), which is dealing with the recent loss of exclusivity for its top-selling drug Singulair, Lilly has to rely on its pipeline to quickly produce drugs with massive market opportunities. In this video, health-care analyst Max Macaluso dives into the company's most worrying patent expiration of 2013.
Eli Lilly’s Biggest Problem in 2013
By Max Macaluso – Feb 8, 2013 at 6:30PM
What is the one risk investors need to know this year?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo